# Satellos Bioscience Inc. (MSCL.TO) fundamentals

Data as of 2026-11-07. TSX, Canada. Sector: Healthcare / Biotechnology. Price C$10.12, market value C$215 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Satellos Bioscience Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -13.5%** (5-yr avg -29.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -89.5%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 21.3%**. Earnings per share rose 21.3%.

## Financial health
- **Current ratio: 7.77** (quick 7.77). Current assets cover the next year's liabilities 7.77 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Satellos Bioscience Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 24.0%** (YTD 27.8%, 3-mo -26.3%). The shares are up 24.0% over twelve months including dividends.
- **From 52-week high: -46.7%** (33.9% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 0.45** (volatility 81%). Beta of 0.45 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MSCL.TO · Page: https://foliofundamentals.com/stocks/mscl.to

Not investment advice.